Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TXMD TherapeuticsMD Inc
- Stocks
- Healthcare
- NASDAQ: TXMD
Price (delayed)
$1.13
Market cap
$13.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.18
Enterprise value
$13.29M
TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women
Highlights
The company's EPS has surged by 74% YoY and by 5% QoQ
The net income has soared by 72% YoY and by 3.7% from the previous quarter
TXMD's debt is up by 8% since the previous quarter but it is down by 6% year-on-year
The equity has contracted by 7% YoY and by 2.3% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.therapeuticsmd.com
Key stats
What are the main financial stats of TXMD
Market
Valuations
Earnings
Shares outstanding
11.57M
Market cap
$13.08M
Enterprise value
$13.29M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.49
Price to sales (P/S)
7.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.22
Revenue
$1.84M
Gross profit
$1.84M
Operating income
-$4.49M
Net income
-$2.1M
EBIT
-$2.16M
EBITDA
-$1.69M
Free cash flow
$479,000
Per share
Balance sheet
Liquidity
EPS
-$0.18
EPS diluted
-$0.18
Free cash flow per share
$0.04
Book value per share
$2.31
Revenue per share
$0.16
TBVPS
$2.95
Total assets
$38.24M
Total liabilities
$11.5M
Debt
$5.96M
Equity
$26.74M
Working capital
$7.77M
Debt to equity
0.22
Current ratio
2.64
Quick ratio
1.84
Net debt/EBITDA
-0.13
Margins
Efficiency
Dividend
EBITDA margin
-91.8%
Gross margin
100%
Net margin
-114.1%
Operating margin
-243.8%
Return on assets
-5.4%
Return on equity
-7.7%
Return on invested capital
-7.2%
Return on capital employed
-6.5%
Return on sales
-117.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TXMD stock price
How has the TherapeuticsMD stock price performed over time
Intraday
4.63%
1 week
-22.07%
1 month
-20.42%
1 year
-47.93%
YTD
31.4%
QTD
22.16%
Financial performance
How have TherapeuticsMD's revenue and profit performed over time
Revenue
$1.84M
Gross profit
$1.84M
Operating income
-$4.49M
Net income
-$2.1M
Gross margin
100%
Net margin
-114.1%
TXMD's net margin has surged by 82% year-on-year and by 8% since the previous quarter
The net income has soared by 72% YoY and by 3.7% from the previous quarter
TXMD's operating margin has surged by 58% year-on-year and by 10% since the previous quarter
The gross profit has soared by 54% YoY and by 4.5% from the previous quarter
Price vs fundamentals
How does TXMD's price correlate with its fundamentals
Growth
What is TherapeuticsMD's growth rate over time
Valuation
What is TherapeuticsMD stock price valuation
P/E
N/A
P/B
0.49
P/S
7.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.22
The company's EPS has surged by 74% YoY and by 5% QoQ
The equity has contracted by 7% YoY and by 2.3% from the previous quarter
The stock's price to book (P/B) is 2% less than its last 4 quarters average of 0.5
TXMD's revenue has soared by 54% year-on-year and by 4.5% since the previous quarter
TXMD's price to sales (P/S) is 32% lower than its last 4 quarters average of 10.5 and 30% lower than its 5-year quarterly average of 10.2
Efficiency
How efficient is TherapeuticsMD business performance
The company's return on sales has surged by 81% YoY and by 7% QoQ
The ROIC has soared by 72% YoY
TherapeuticsMD's ROE has soared by 70% YoY and by 2.5% from the previous quarter
TXMD's return on assets has surged by 65% year-on-year
Dividends
What is TXMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TXMD.
Financial health
How did TherapeuticsMD financials performed over time
TXMD's quick ratio has surged by 57% year-on-year and by 10% since the previous quarter
TherapeuticsMD's current ratio has increased by 48% YoY and by 11% from the previous quarter
TXMD's debt is 78% smaller than its equity
TXMD's debt to equity is up by 10% since the previous quarter
TXMD's debt is up by 8% since the previous quarter but it is down by 6% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.